Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2020 16:07 ET | Source: Equillium

Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital

LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
March 26, 2020 16:07 ET | Source: Equillium

Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update

EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., March ...
February 27, 2020 16:13 ET | Source: Equillium

Equillium Strengthens Leadership Team with Key Appointments

Maple Fung, M.D., joins as vice president clinical developmentMatthew Ritter, Ph.D., joins as vice president corporate development LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Equillium,...
February 13, 2020 16:07 ET | Source: Equillium

Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference

LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
January 29, 2020 16:07 ET | Source: Equillium

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR

LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
December 12, 2019 07:00 ET | Source: Equillium; Biocon Ltd

Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

LA JOLLA, Calif. and BENGALURU, India, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop...
December 09, 2019 16:10 ET | Source: Equillium

Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis

LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
November 26, 2019 16:07 ET | Source: Equillium

Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition

LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
November 15, 2019 08:05 ET | Source: Equillium

Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health

LA JOLLA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
November 12, 2019 16:07 ET | Source: Equillium

Equillium Announces Leadership Updates

Effective January 1, 2020 Bruce Steel will assume role of Chief Executive Officer, and Dan Bradbury will remain on the Board of Directors as Executive Chairman Krishna Polu, M.D., and Christine...